BCR-ABL is a fusion gene formed by the rearrangement of breakpoint cluster region (BCR) on chromosome 22 with the ABL protooncogene on chromosome 9 leading to the formation of Philadelphia chromosome. This rearrangement is seen in almost 95% patients with CML. The Quantitative assay helps in the management of the disease and monitors effect of therapy.

  • Test Type:
  • Pre-test Information:
    MRD Clinical information form with historical data is mandatory
  • Report Delivery:
    Sample by Mon / Wed / Fri 9 am; Report Tue / Thu / Sat
  • Components: